FDA Approves Drug For Rare Disease Without Clinical Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Orphan Europe's Carbaglu approval was based on a retrospective analysis of case studies - but FDA has said it should not be viewed as a precedent.